SNSS:NASDAQ

Sunesis Pharmaceuticals Inc.

Sunesis Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The company has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, vosaroxin, in multiple indications to improve the lives of people with cancer.

Expert Comments:

Mara Goldstein, Cantor Fitzgerald (5/14/15)
"We maintain a Buy and $4 price target based on our view that Sunesis Pharmaceuticals Inc. will submit a new drug application for Qinprezo for the treatment of acute myelogenous leukemia, later this year, and that will allow the shares to be revalued. . .cash of $47M is expected to provide the company with funds through mid-2016."

Matthew Andrews, Wells Fargo Securities (5/14/15)
"Abstract 7055 for Sunesis Pharaceuticals Inc.'s vosaroxin presented at the American Society of Clinical Oncology's annual meeting notes a higher proportion of 60+ year olds treated with vosaroxin plus cytarabine and subsequently underwent allogeneic transplant achieved a pre-transplant complete remission, resulting in an overall survival trend favoring vosaroxin plus cytarabine (20.2 versus 12.2 months; p=0.088)."

"Sunesis Pharmaceuticals Corp. is targeting its formal meeting with the FDA in mid-2015 and, if successful, a rolling new drug application (NDA) submission in H2/15 based on fast-track status. In the European Union, the company has been assigned rapporteurs and plans to meet with the European Medicines Agency in mid-2015 to discuss its marketing authorization application filing. . .we maintain our Buy rating." read more >

Matthew Andrews, Wells Fargo Securities (5/6/15)
"Prior to the May 5, 2015 market open, Sunesis Pharmaceuticals Inc. reported Q1/15 results for a quarter highlighted by completion of preclinical toxicology studies for SNS-062 and continued ongoing progress on the Qinprezo relapsed/refractory acute myeloid leukemia regulatory fronts with the company engaging in a 'data-driven' dialog with the U.S. Food and Drug Administration. . .cash on hand at March 31, 2015 was $39.8M. . .Sunesis believes cash on hand extends operations into Q2/16."

Joseph Pantginis, ROTH Capital Partners (5/5/15)
"Sunesis Pharmaceuticals Inc. is targeting its formal meeting with the U.S. Food and Drug Administration in mid-2015 and, if successful, a rolling new drug application submission in H2/15 based on fast track status. In the European Union, the company has been assigned rapporteurs and plans to meet with the European Medicines Agency in mid-2015 to discuss its marketing authorization application filing. . .we maintain our Buy rating."

Hartaj Singh, BTIG Research (5/5/15)
"Sunesis Pharmaceuticals Inc. reported Q1/15 earnings, demonstrating excellent operating expenditure control while also managing to raise additional monies (via an at the market) to extend its cash runway from early 2016 to mid-2016. . .we are very intrigued with the company's preclinical kinase inhibitor program, especially the BTK and PDK1 programs. We reiterate our bullish thesis."

Management Q&A: View From the Top
Daniel Swisher, Jr.
Daniel N. Swisher Jr., president and CEO of Sunesis Pharmaceuticals Inc., describes how his company is making clinical progress toward developing a new treatment for acute myelogenous leukemia, and how the broad Sunesis kinase inhibitor portfolio provides additional firepower against other cancers.
read more >

More Expert Comments

Experts Commenting on This Company

Matthew Andrews
Reni Benjamin
Stephen Dunn
Mara Goldstein
David Nierengarten
Joseph Pantginis
Hartaj Singh
George Zavoico

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
Investing Highlights
 
Totality of VALOR data shows compelling risk-benefit trade-off in disease with significant unmet need
 
Relapsed/refractory AML is a significant commercial opportunity with no approved agents
 
Our kinase inhibitor pipeline is poised to progress to the clinic in 2015 and 2016
catalyst Calendar
Sunesis Pharmaceuticals Inc. Content